A majority of cases of asthma encountered in the first decade of life can be classified as "infective asthma."1 This condition is characterized by association of asthmatic attacks with episodes of infection and by lack of demonstrable allergic etiology. Most conventional therapeutic approaches to the problem of prevention of such attacks have been disappointing in their results. In 1963, Baker,2 as well as Salmon and Symonds,3 had claimed beneficial effects on chronic childhood asthma from injections with staphylococcus bacteriophage lysate vaccine (staphage lysate). This material is produced from broth cultures of virulent strains of coagulase-positive Staphylococcus aureus, serologic types I and III, which have been lysed by a bacteriophage. Material and Methods Forty-four children with "infective asthma," who had been followed for at least one year prior to study in the Outpatient Department of Jersey City Medical Center and who had shown definite association of asthma with